# Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

> **NCT07020247** · PHASE3 · RECRUITING · sponsor: **West China Hospital** · enrollment: 184 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)
- Immunotherapy
- Radiotherapy
- Total Neoadjuvant Therapy
- Anal Function Preservation

## Interventions

- **DRUG:** Anti-PD-1 antibody drug named Serplulimab
- **RADIATION:** Radiotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07020247
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-19
- **Primary completion:** 2027-07-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020247, "Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07020247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*